KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Sep 2025 value amounting to $10.1 million.

  • Rigel Pharmaceuticals' Accumulated Expenses rose 27.02% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 27.02%. This contributed to the annual value of $10.1 million for FY2024, which is 16.86% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Accumulated Expenses stood at $10.1 million, which was up 27.45% from $7.9 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Accumulated Expenses high stood at $10.7 million for Q4 2021, and its period low was $5.2 million during Q1 2024.
  • In the last 3 years, Rigel Pharmaceuticals' Accumulated Expenses had a median value of $7.9 million in 2025 and averaged $7.5 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first dropped by 17.06% in 2022, then rose by 27.02% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $10.7 million in 2021, then decreased by 17.06% to $8.9 million in 2022, then declined by 2.14% to $8.7 million in 2023, then rose by 16.86% to $10.1 million in 2024, then climbed by 27.02% to $10.1 million in 2025.
  • Its Accumulated Expenses was $10.1 million in Q3 2025, compared to $7.9 million in Q2 2025 and $6.0 million in Q1 2025.